Technical analysis of Delcath Systems, Inc. (DCTH): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects.
Price Performance
| 1 month | -3.80% |
| 3 months | +38.75% |
| Year-to-date | +60.59% |
| 1 year | +44.82% |
| 3 years | +268.64% |
| 5 years | +77.85% |
52-Week Range
| 52-week High | $17.42 |
| 52-week Low | $8.12 |
| Avg Volume (90d) | 527K |
Technical Indicators
| SMA 50 | $14.87 |
| SMA 200 | $11.51 |
| Beta | 0.43 |
| 30-day Volatility (annualised) | 71.0% |
| Price vs SMA 50 | +9.1% |
| Price vs SMA 200 | +40.9% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $9.83 | |
| 2025-11 | $9.70 | -1.3% |
| 2025-12 | $10.10 | +4.1% |
| 2026-01 | $9.91 | -1.9% |
| 2026-02 | $8.90 | -10.2% |
| 2026-03 | $9.28 | +4.3% |
| 2026-04 | $10.38 | +11.9% |
| 2026-05 | $10.78 | +3.9% |
| 2026-06 | $12.59 | +16.8% |
| 2026-07 | $12.22 | -2.9% |
| 2026-08 | $16.46 | +34.7% |
| 2026-09 | $16.22 | -1.5% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $-0.26 | $14M |
| 2026-09-14 | | |
| 2026-09-14 | $0.84 | $26M |
| 2026-09-14 | | |
Price
| Price | $16.22 |
| Market Cap | $560M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 1467.87 |
| Price / Book | 4.78 |
| EV / EBITDA | 297.45 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 9.83 |